SG10201803812TA - Neuroactive steroids, compositions, and uses thereof - Google Patents

Neuroactive steroids, compositions, and uses thereof

Info

Publication number: SG10201803812TA
Authority: SG; Singapore
Prior art keywords: disorders; compositions; treatment; steroids; neuroactive steroids
Prior art date: 2014-05-29

Application number

SG10201803812TA

Other languages

English (en)

Inventor

Gabriel Martinez Botella

Boyd L Harrison

Albert Jean Robichaud

Francesco G Salituro

Richard Thomas Beresis

Original Assignee

Sage Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-29

Filing date

2015-05-29

Publication date

2018-06-28

2015-05-29 Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc

2018-06-28 Publication of SG10201803812TA publication Critical patent/SG10201803812TA/en

Links

150000003431 steroids Chemical class 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 3
206010010904 Convulsion Diseases 0.000 abstract 1
208000019022 Mood disease Diseases 0.000 abstract 1
208000016285 Movement disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
208000009205 Tinnitus Diseases 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
208000029560 autism spectrum disease Diseases 0.000 abstract 1
230000019771 cognition Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
230000036407 pain Effects 0.000 abstract 1
208000022821 personality disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
238000001228 spectrum Methods 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
231100000886 tinnitus Toxicity 0.000 abstract 1
230000009529 traumatic brain injury Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Epidemiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hospice & Palliative Care (AREA)

SG10201803812TA 2014-05-29 2015-05-29 Neuroactive steroids, compositions, and uses thereof SG10201803812TA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN2014078820		2014-05-29

Publications (1)

Publication Number	Publication Date
SG10201803812TA true SG10201803812TA (en)	2018-06-28

Family

ID=54698130

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201609813XA SG11201609813XA (en)	2014-05-29	2015-05-29	Neuroactive steroids, compositions, and uses thereof
SG10201803812TA SG10201803812TA (en)	2014-05-29	2015-05-29	Neuroactive steroids, compositions, and uses thereof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201609813XA SG11201609813XA (en)	2014-05-29	2015-05-29	Neuroactive steroids, compositions, and uses thereof

Country Status (26)

Country	Link
US (5)	US20180179247A1 (es)
EP (3)	EP3705488B1 (es)
JP (4)	JP6652934B2 (es)
KR (2)	KR102494061B1 (es)
CN (3)	CN106661078A (es)
AR (2)	AR100691A1 (es)
AU (4)	AU2015266447A1 (es)
CA (1)	CA2949720A1 (es)
CY (1)	CY1124109T1 (es)
DK (2)	DK3705488T3 (es)
ES (2)	ES2805598T3 (es)
HR (2)	HRP20221294T1 (es)
HU (2)	HUE059829T2 (es)
IL (3)	IL292461B2 (es)
JO (1)	JO3691B1 (es)
LT (2)	LT3705488T (es)
MX (4)	MX2016015532A (es)
PH (1)	PH12016502342A1 (es)
PL (2)	PL3705488T3 (es)
PT (2)	PT3705488T (es)
RS (2)	RS60529B1 (es)
RU (2)	RU2699359C2 (es)
SG (2)	SG11201609813XA (es)
SI (2)	SI3705488T1 (es)
TW (1)	TW201625661A (es)
WO (1)	WO2015180679A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ568700A (en)	2005-11-28	2012-03-30	Marinus Pharmaceuticals	Solid stabilized particulate formulations comprising ganaxolone
CN108976272B (zh)	2011-10-14	2021-05-25	萨奇治疗股份有限公司	3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169836A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en)	2013-04-17	2017-08-08	Sage Therapeutics, Inc.	19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
KR20230172622A (ko)	2013-04-17	2023-12-22	세이지 테라퓨틱스, 인크.	19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
HUE051403T2 (hu)	2013-04-17	2021-03-01	Sage Therapeutics Inc	Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz
PT3021852T (pt)	2013-07-19	2021-04-21	Sage Therapeutics Inc	Esteroides neuroativos, composições e utilizações das mesmas
CA2921512A1 (en)	2013-08-23	2015-02-26	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
HRP20221294T1 (hr) *	2014-05-29	2023-03-03	Sage Therapeutics, Inc.	Neuroaktivni steroidi, njihovi pripravci i uporabe
WO2015195962A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en)	2014-10-16	2020-03-03	Sage Therapeutics, Inc.	Compositions and methods for treating CNS disorders
HUE051488T2 (hu)	2014-10-16	2021-03-01	Sage Therapeutics Inc	Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
EP3719029A1 (en)	2014-11-27	2020-10-07	Sage Therapeutics, Inc.	Compositions for inducing sedation
DK3250210T3 (da)	2015-01-26	2021-03-08	Sage Therapeutics Inc	Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
US10329320B2 (en)	2015-02-20	2019-06-25	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
US10780099B2 (en)	2015-10-16	2020-09-22	Marinus Pharmaceuticals, Inc.	Injectable neurosteroid formulations containing nanoparticles
MA43815A (fr) *	2016-03-08	2021-04-07	Sage Therapeutics Inc	Stéroïdes neuroactifs, compositions, et leurs utilisations
AU2017296295B2 (en) *	2016-07-11	2022-02-24	Sage Therapeutics, Inc.	C7, C12, and C16 substituted neuroactive steroids and their methods of use
RU2019103590A (ru) *	2016-07-11	2021-02-11	Сейдж Терапьютикс, Инк.	С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения
KR20230050474A (ko)	2016-08-11	2023-04-14	오비드 테라퓨틱스 인크.	간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en)	2016-09-09	2019-08-27	Marinus Pharmaceuticals Inc.	Methods of treating certain depressive disorders and delirium tremens
US20200291059A1 (en)	2017-12-08	2020-09-17	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
BR112020016269A2 (pt)	2018-02-11	2020-12-15	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Reguladores derivados de esteroides, método para prepará- los e suas utilizações
CN109503694A (zh) *	2018-11-21	2019-03-22	苏州闻天医药科技有限公司	一种新型gabaa受体调节剂及其用途
US11266662B2 (en)	2018-12-07	2022-03-08	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in prophylaxis and treatment of postpartum depression
KR20210116523A (ko) *	2019-01-14	2021-09-27	베이징 슈안이 파마사이언시스 컴퍼니, 리미티드	테트라졸론 치환된 스테로이드 및 이의 용도
JP2022534424A (ja)	2019-05-31	2022-07-29	セージセラピューティクス，インコーポレイテッド	神経刺激性ステロイド及びその組成物
JP2022543837A (ja)	2019-08-05	2022-10-14	マリナスファーマシューティカルズ，インコーポレイテッド	てんかん重積状態の治療に使用するためのガナキソロン
KR20220066262A (ko)	2019-08-07	2022-05-24	상하이 한서 바이오메디컬 컴퍼니 리미티드	스테로이드 유도체 조절제의 염 및 결정형
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
JP2023503928A (ja)	2019-12-06	2023-02-01	マリナスファーマシューティカルズ，インコーポレイテッド	結節性硬化症の治療での使用のためのガナキソロン
WO2022165017A1 (en)	2021-01-28	2022-08-04	Sage Therapeutics, Inc.	Use of neuroactive steroids for treatment of sexual dysfunction
KR20240037975A (ko)	2021-07-28	2024-03-22	세이지 테라퓨틱스, 인크.	신경활성 스테로이드의 결정질 형태
WO2023164387A1 (en)	2022-02-28	2023-08-31	Sage Therapeutics, Inc.	Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024026337A1 (en)	2022-07-27	2024-02-01	Sage Therapeutics, Inc.	Crystalline forms of a neuroactive steroid
WO2024059608A1 (en)	2022-09-15	2024-03-21	Sage Therapeutics, Inc.	Deuterated neuroactive steroids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3634717A1 (de) *	1986-10-11	1988-04-14	Dynamit Nobel Ag	Verfahren zur herstellung von 5-methyltetrazol
US5232917A (en)	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5939545A (en) *	1994-02-14	1999-08-17	Cocensys, Inc.	Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
JP4066272B2 (ja) *	1994-02-14	2008-03-26	ユーロ‐セルティックエス．ア．	Ｇａｂａ受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類
AU3967297A (en) *	1996-08-01	1998-02-25	Cocensys, Inc.	Use of gaba and nmda receptor ligands for the treatment of migraine headache
CA2372342A1 (en) *	1999-04-29	2000-11-09	Derk J. Hogenkamp	3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
ATE537748T1 (de) *	2002-10-15	2012-01-15	Medtronic Inc	Medizinisches vorrichtungssystem zur bewertung von gemessenen neurologischen ereignissen
US7729773B2 (en) *	2005-10-19	2010-06-01	Advanced Neuromodualation Systems, Inc.	Neural stimulation and optical monitoring systems and methods
CN108976272B (zh) *	2011-10-14	2021-05-25	萨奇治疗股份有限公司	3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
HRP20221294T1 (hr) *	2014-05-29	2023-03-03	Sage Therapeutics, Inc.	Neuroaktivni steroidi, njihovi pripravci i uporabe
HUE051488T2 (hu) *	2014-10-16	2021-03-01	Sage Therapeutics Inc	Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére

2015
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/hr unknown
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/ru active
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-29 TW TW104117532A patent/TW201625661A/zh unknown
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/lt unknown
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/ja active Active
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 AR ARP150101717A patent/AR100691A1/es active IP Right Grant
- 2015-05-29 RS RS20200799A patent/RS60529B1/sr unknown
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/da active
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/hu unknown
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/ko active IP Right Grant
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/lt unknown
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/zh active Pending
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/pl unknown
- 2015-05-29 RS RS20220848A patent/RS63554B1/sr unknown
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/hu unknown
- 2015-05-29 SI SI201531879T patent/SI3705488T1/sl unknown
- 2015-05-29 ES ES15799762T patent/ES2805598T3/es active Active
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/ko active Application Filing
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 PT PT201716701T patent/PT3705488T/pt unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/zh active Pending
- 2015-05-29 PT PT157997628T patent/PT3149018T/pt unknown
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-29 MX MX2016015532A patent/MX2016015532A/es unknown
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/zh active Pending
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 ES ES20171670T patent/ES2927007T3/es active Active
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/ru unknown
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/da active
- 2015-05-29 SI SI201531252T patent/SI3149018T1/sl unknown
- 2015-05-29 PL PL15799762T patent/PL3149018T3/pl unknown
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/ar active
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/es unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/es unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/es unknown
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/ja active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-17 HR HRP20201126TT patent/HRP20201126T1/hr unknown
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/el unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/es unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/ja active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/ja active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en active Pending
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending

Also Published As

Publication number	Publication date
AU2023285755A1 (en)	2024-01-18
SI3705488T1 (sl)	2022-10-28
US20200165291A1 (en)	2020-05-28
HRP20201126T1 (hr)	2020-12-11
DK3149018T3 (da)	2020-07-20
MX2021005106A (es)	2021-06-15
MX2021005099A (es)	2021-06-15
JP7386204B2 (ja)	2023-11-24
AU2015266447A1 (en)	2016-12-01
HUE059829T2 (hu)	2022-12-28
AU2019279910A1 (en)	2020-01-16
CA2949720A1 (en)	2015-12-03
RS60529B1 (sr)	2020-08-31
LT3149018T (lt)	2020-08-10
IL248948A0 (en)	2017-01-31
EP3705488B1 (en)	2022-08-03
SG11201609813XA (en)	2016-12-29
AU2021204410A1 (en)	2021-07-22
RU2016151727A (ru)	2018-07-02
PT3149018T (pt)	2020-07-21
ES2805598T3 (es)	2021-02-12
AR121661A2 (es)	2022-06-29
HRP20221294T1 (hr)	2023-03-03
AU2021204410B2 (en)	2023-09-21
IL304033A (en)	2023-08-01
PH12016502342A1 (en)	2017-02-13
PL3149018T3 (pl)	2021-01-25
EP3149018B1 (en)	2020-04-29
TW201625661A (zh)	2016-07-16
NZ764921A (en)	2023-11-24
RU2016151727A3 (es)	2018-12-03
US20210061850A1 (en)	2021-03-04
MX2016015532A (es)	2017-02-27
CN106661078A (zh)	2017-05-10
TW202231652A (zh)	2022-08-16
KR20230021165A (ko)	2023-02-13
EP3149018A4 (en)	2017-12-06
CN114369135A (zh)	2022-04-19
AR100691A1 (es)	2016-10-26
JP2023123878A (ja)	2023-09-05
CY1124109T1 (el)	2022-03-24
LT3705488T (lt)	2022-09-26
RU2699359C2 (ru)	2019-09-05
MX2023004352A (es)	2023-05-08
JP2021130696A (ja)	2021-09-09
CN114133423A (zh)	2022-03-04
NZ726260A (en)	2023-11-24
EP3705488A1 (en)	2020-09-09
JO3691B1 (ar)	2020-08-27
JP2017516793A (ja)	2017-06-22
IL292461B1 (en)	2023-11-01
KR20240066304A (ko)	2024-05-14
BR112016027508A2 (pt)	2018-06-26
ES2927007T3 (es)	2022-10-31
PL3705488T3 (pl)	2022-12-05
PT3705488T (pt)	2022-09-30
IL248948B (en)	2022-09-01
IL292461B2 (en)	2024-03-01
JP6652934B2 (ja)	2020-02-26
JP6892936B2 (ja)	2021-06-23
JP2020073577A (ja)	2020-05-14
DK3705488T3 (da)	2022-10-03
SI3149018T1 (sl)	2020-10-30
HUE050028T2 (hu)	2021-12-28
NZ764941A (en)	2023-11-24
WO2015180679A1 (en)	2015-12-03
EP3149018A1 (en)	2017-04-05
US20210061849A1 (en)	2021-03-04
RS63554B1 (sr)	2022-09-30
KR20170003706A (ko)	2017-01-09
KR102494061B1 (ko)	2023-01-31
US20180179247A1 (en)	2018-06-28
AU2019279910B2 (en)	2021-07-22
RU2019126637A (ru)	2019-10-03
US20240076310A1 (en)	2024-03-07
EP4144746A1 (en)	2023-03-08
IL292461A (en)	2022-06-01

Publication	Publication Date	Title
PH12016502342A1 (en)	2017-02-13	Neuroactive steroids, compositions, and uses thereof
MX2022007490A (es)	2022-07-05	Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
CY1124175T1 (el)	2022-03-24	Νευροδραστικα στεροειδη 19-nor για μεθοδους θεραπευτικης αντιμετωπισης
PH12020551315A1 (en)	2021-07-05	Benzoxazepin oxazolidinone compounds and methods of use
MX2023001876A (es)	2023-03-10	Derivados de rapamicina.
GEP20207172B (en)	2020-10-26	1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
NZ711119A (en)	2020-08-28	Trk-inhibiting compound
EA201200952A1 (ru)	2013-02-28	Производные пиразина и их применение для лечения неврологических нарушений
MX2016015248A (es)	2017-02-23	Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
UA109459C2 (xx)	2015-08-25	ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
WO2011097946A8 (zh)	2012-07-26	含有并环稠合双环的噁唑烷酮化合物及其制备和应用
MX2013008056A (es)	2013-08-09	1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2019007101A (es)	2019-12-16	Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
PH12019500497A1 (en)	2019-12-11	Heteroaryl carboxamide compounds as inhibitors of ripk2
MX2019007100A (es)	2019-12-16	Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
MY196807A (en)	2023-05-03	Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
MX2019007102A (es)	2019-12-16	Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2016015180A (es)	2017-03-23	Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a.
MX2013002956A (es)	2013-05-09	Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
GEP20156227B (en)	2015-01-26	Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
MX2017009853A (es)	2017-11-01	Prevencion o tratamiento de enfermedades urinarias o gotosas.
NZ764941B2 (en)	2024-02-28	Neuroactive steroids, compositions, and uses thereof
MD20160115A2 (ro)	2017-02-28	Combinaţie nouă dintre 8-ciclopropil-3-[2-(3-fluorofenil)etil]-7,8-dihidro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazin-4,9-dionă şi un inhibitor al acetilcolinesterazei şi compoziţii farmaceutice care o conţin
UA107356C2 (en)	2014-12-25	Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
GEP20135801B (en)	2013-04-10	New compounds of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them